ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2929

Cannabis Use Among Patients in a Large US Rheumatic Disease Registry

Kristin Wipfler 1, Teresa Simon2, Patricia Katz 3, Frederick Wolfe 4 and Kaleb Michaud 5, 1FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 2Bristol-Myers Squibb*, Princeton, NJ, 3University of California, San Francisco, san francisco, CA, 4FORWARD, The National Databank for Rheumatic Diseases & University of Nebraska Medical Center, Wichita, KS, 5FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cannabinoid, Chronic pain, marijuana, opioids and prescribing trends

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 13, 2019

Session Title: 6W026: Epidemiology & Public Health (2924–2929)

Session Type: ACR/ARP Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Legalization of cannabis use is rapidly increasing worldwide, raising the need to evaluate trends and medical implications. A systematic literature review showed inconsistent results on tolerability and safety of cannabis-based medicines for any chronic pain [1]. Additionally, little is known about the use and effectiveness of cannabis in rheumatic diseases [2]. We sought to evaluate the trends of cannabis use and associations with rheumatic disease characteristics in a US-wide registry.

Methods: Study patients were participants in FORWARD, The National Databank for Rheumatic Diseases, a longitudinal study of rheumatic disease outcomes, who indicated in a 2014 and/or 2019 questionnaire whether they had ever used marijuana, cannabis, or cannabidiol (hereafter cannabis) for symptom relief, and if so, whether they found it helpful. Demographics, disease activity/status assessments (PRO), medications, comorbidities, and diagnosis were compared between cannabis users and nonusers in 2014 and 2019. Significance was assessed using t-tests and Chi-square tests as appropriate. Choropleth maps were generated based on prevalence of cannabis use in each US state. Logistic regression models were generated to determine the probability of cannabis or opioid use by polysymptomatic distress (the score used to determine whether fibromyalgia criteria are met).

Results: Among the 11,006 unique respondents, the prevalence of past or current cannabis use has increased from 6.3% in 2014 to 17.6% in 2019. At both time points, patients reporting use were younger, had worse measures on all PROs, and were more likely to have a history of smoking cigarettes, have fibromyalgia, report a history of depression, and report opioid use (Table 1). In 2014, users were also less likely to be Caucasian, married, and have health insurance. In 2019 there were fewer demographic differences. Most patients reported that cannabis was helpful in relieving symptoms (74% in 2014 and 62% in 2019). Since 2014, prevalence of use increased in 49 of 50 US states, with the highest prevalence in and near states where cannabis use is legal (Figure 1). Logistic regression models indicate that the probability of cannabis use increases with increasing polysymptomatic distress, and the same is true for opioid use (Figure 2).

Conclusion: Reported cannabis use among patients with rheumatic diseases has increased significantly, and most patients stated it was helpful for symptom relief. Patients who tried cannabis tended to have worse pain, disease activity, and symptoms and were taking more analgesics. While interpretation of cannabis effectiveness is beyond our study’s scope, the association with prior opioid use and polysymptomatic distress highlights areas for future work.

References:

1 Häuser W W, Petzke F  Fitzcharles MA; Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management – An overview of systematic reviews.  European j Pain, volume 22, issue 3, 2018.

2 Fitzcharles MA,  Niaki Z, Omid O, Hauser WW, Hazlewood G, et.al. A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.;2019 Jan 15; J. Rheumatol.

Table 1. Demographics, disease activity/status assessments, medications, comorbidities, and diagnoses among cannabis users and nonusers in 2014 and 2019. Values are mean +/- standard deviation unless indicated otherwise. Bold p values indicate statistical significance.

Figure 1. Prevalence of cannabis use in patients with rheumatic diseases and legality of cannabis by US state in 2014 and 2019. Mean n per state was 184 in 2014 and 88 in 2019. Maps were generated with Plotly.

Figure 2. Adjusted predictions with 95% confidence intervals for cannabis use -A- and opioid use -B- by polysymptomatic distress score.


Disclosure: K. Wipfler, Option Care, 3; T. Simon, Bristol-Myers Squibb, 3; P. Katz, None; F. Wolfe, None; K. Michaud, Pfizer, 2, Rheumatology Research Foundation, 2.

To cite this abstract in AMA style:

Wipfler K, Simon T, Katz P, Wolfe F, Michaud K. Cannabis Use Among Patients in a Large US Rheumatic Disease Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cannabis-use-among-patients-in-a-large-us-rheumatic-disease-registry/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cannabis-use-among-patients-in-a-large-us-rheumatic-disease-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences